Last updated: July 29, 2026
Onyx v. Cipla (1:16-cv-00988-LPS): Litigation summary, patent positions, and what it means for generic entry risk
Onyx Therapeutics, Inc. sued Cipla Ltd. in the Eastern District of Texas under 35 U.S.C. § 271(e)(2) (Paragraph IV framework) in Onyx Therapeutics, Inc. v. Cipla Limited, No. 1:16-cv-00988-LPS. The case centers on patent infringement allegations tied to Cipla’s FDA Abbreviated New Drug Application (ANDA) for a covered product in Onyx’s portfolio. The litigation posture and outcomes determine the practical window for generic launch by constraining Cipla’s regulatory path until patent expiry or a non-infringement/invalidity finding.
However, the specific patent numbers asserted, the asserted drug/ANDA number, procedural timeline, claim construction results, dispositive rulings, and final judgment terms are not included in the provided information. Without those facts, a complete and accurate infringement and litigation analysis cannot be produced.
What can be stated from the docket identifier alone
- Forum: Eastern District of Texas.
- Case name: Onyx Therapeutics, Inc. v. Cipla Limited.
- Case number: 1:16-cv-00988-LPS.
- Legal posture (by statute): § 271(e)(2) patent infringement suit is typically tied to ANDA/Paragraph IV conduct, but the statute-by-filing inference cannot substitute for asserted-patent and outcome facts.
What patents were asserted in Onyx Therapeutics v. Cipla (1:16-cv-00988-LPS)?
Answer (required facts): Not stated in the information provided. Patent-by-patent analysis requires the asserted patent numbers, their titles/claim scopes, and the infringement/invalidity theories.
What filings usually matter to extract
- Complaint asserting specific Orange Book patents (U.S. patents with FDA listing).
- CIPLA’s ANDA and Paragraph IV notice identifying each patent challenged.
- Onyx’s infringement chart mapping ANDA product claims to specific dosage strengths and manufacturing parameters.
- Any amended complaints adding/removing patents.
How did the court rule on infringement, invalidity, and claim construction in 1:16-cv-00988-LPS?
Answer (required facts): Not stated in the information provided. A meaningful litigation summary requires:
- claim construction orders,
- summary judgment outcomes,
- trial verdicts (if any),
- final judgment,
- whether patents were held invalid, non-infringed, or settled.
Was this case resolved by settlement, dismissal, or a final judgment in favor of Onyx or Cipla?
Answer (required facts): Not stated in the information provided. Resolution type directly changes generic entry interpretation:
- Settlement may impose design-around or market-entry timing.
- Dismissal may reflect lack of justiciability or failure to prove infringement.
- Final judgment defines a legal precedent and the immediate enforceability of the estate.
What Paragraph IV ANDA challenge drove Onyx v. Cipla in 1:16-cv-00988-LPS?
Answer (required facts): Not stated in the information provided. The ANDA number and proposed product strength/dosage form must be known to connect patent claims to the generic design and to quantify launch risk.
What to extract for entry-risk modeling (not provided)
- ANDA number (e.g., with specific proposed product).
- Paragraph IV notice date.
- Whether Onyx sought a preliminary injunction.
- Whether the court issued any stay or injunction order.
Orange Book status: which Onyx-listed patents were implicated in the Onyx v. Cipla case?
Answer (required facts): Not stated in the information provided. Orange Book status analysis requires:
- the drug name,
- the listed patents,
- their expiration dates,
- and whether they were “effective” at the time of the ANDA filing.
How does the litigation outcome affect Cipla’s generic launch timing and “safe-to-market” risk?
Answer (required facts): Not stated in the information provided. Launch timing depends on:
- whether the case reached merits,
- whether Onyx patents were invalidated or found not infringed,
- whether any settlement triggered entry-date commitments,
- and whether the FDA approval was constrained by a statutory stay.
What is the strength of Onyx’s patent estate based on this litigation record?
Answer (required facts): Not stated in the information provided. Estate strength analysis requires:
- which patents survived,
- claim construction outcomes,
- and the level of specificity Onyx demonstrated in infringement.
Does this case inform biosimilar or formulation design-around risk (if applicable)?
Answer (required facts): Not stated in the information provided. Onyx v. Cipla could involve small molecules or biologics, but biosimilar-specific implications require:
- identification of whether the product is a biologic,
- whether the case involved expression systems, formulation, or method-of-use claims.
How does Onyx v. Cipla compare with other Onyx ANDA litigations in the Eastern District of Texas?
Answer (required facts): Not stated in the information provided. A comparison requires:
- companion cases and their outcomes,
- overlap in asserted patents,
- and whether Cipla appears in similar disputes.
Key Takeaways
- The litigation identifier Onyx Therapeutics, Inc. v. Cipla Limited, 1:16-cv-00988-LPS is provided, but the asserted patents, procedural history, and outcome are not included.
- Without the asserted patent numbers and final disposition, a litigation summary and infringement/invalidity analysis cannot be completed to a litigation-grade standard.
- Any assessment of generic entry risk, Orange Book timing, or enforceability depends directly on facts missing from the prompt.
FAQs
- What does a § 271(e)(2) case number format like 1:16-cv-00988-LPS imply about the underlying ANDA challenge?
- How do claim construction rulings typically affect infringement and validity outcomes in Paragraph IV litigation?
- What role do Orange Book “listed” patents play in determining which claims a court can adjudicate?
- How do settlement terms in ANDA litigations translate into launch-date constraints for generic manufacturers?
- What litigation milestones most strongly predict whether a court will grant or deny injunctive relief in generic patent cases?
References
- Not provided in the prompt.
